Stock Price
11.31
Daily Change
-5.91%
Yearly
-44.99%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 2,576.50 108.00 4.38% -25.66%
AbbVie 135.97 1.74 1.30% 30.48%
Amgen 224.00 1.54 0.69% -9.59%
AstraZeneca 8,757.00 -79.00 -0.89% 14.49%
Biogen 218.94 -0.40 -0.18% -18.27%
Bristol-Myers Squibb 63.86 1.63 2.61% 2.52%
Cerulean Pharma 1.43 -0.05 -3.38% -33.80%
Dicerna Pharmaceuticals 38.22 0.22 0.58% 71.54%
Epizyme 1.06 -0.84 -44.21% -90.68%
Five Prime Therapeutics 38.00 0 0% 1,339.39%
Genmab 2,127.00 -30.00 -1.39% -14.65%
Geron 1.01 -0.03 -2.83% -40.94%
Gilead Sciences 67.27 -0.07 -0.10% 4.00%
Immunogen 5.09 -0.22 -4.14% -29.50%
J&J 170.69 2.31 1.37% 0.90%
Karyopharm Therapeutics 7.83 -0.86 -9.85% -47.83%
Eli Lilly 236.70 -1.13 -0.48% 12.65%
MacroGenics 11.31 -0.71 -5.91% -44.99%
Merck & Co 80.57 1.41 1.78% 3.40%
Mirati Therapeutics 107.83 -5.15 -4.56% -47.11%
Puma Biotechnology 2.25 -0.08 -3.22% -80.90%
Pfizer 53.37 0.36 0.68% 48.83%
Regeneron Pharmaceuticals 608.72 2.52 0.42% 20.24%
Roche Holding 353.85 -0.75 -0.21% 11.61%
Seattle Genetics 122.91 -0.64 -0.52% -24.40%
Xencor 31.92 -1.75 -5.22% -31.49%

Indexes Price Day Year
NASDAQ 13353 -189.34 -1.40% 0.12%
US2000 1931 -45.18 -2.29% -8.32%

MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.